FIELD: biotechnology.
SUBSTANCE: group of inventions relates to biotechnology, immunology and virology. What is presented is a heavy-chain monoclonal antibody specifically binding to the S protein of the SARS-CoV-2 virus. Heavy-chain monoclonal antibody has virus-neutralizing activity and has the amino acid sequence SEQ ID NO: 1 or SEQ ID NO: 2. Also disclosed is a nucleic acid having a nucleotide sequence coding said heavy-chain monoclonal antibody, a producer cell containing said nucleic acid, and a method of treating a disease caused by the SARS-CoV-2 virus using said heavy-chain monoclonal antibody.
EFFECT: group of inventions provides the creation of heavy-chain monoclonal antibodies which effectively bind the S protein of the SARS-CoV-2 virus, neutralize the SARS-CoV-2 virus and can be used for therapy of diseases caused by SARS-CoV-2 virus; in addition, the developed antibody has a wide spectrum of virus-neutralizing activity against various variants of the SARS-CoV-2 virus.
6 cl, 9 dwg, 5 tbl, 7 ex
| Title | Year | Author | Number |
|---|---|---|---|
| SINGLE-DOMAIN ANTIBODY AND ITS MODIFICATIONS THAT SPECIFICALLY BIND TO RBDS PROTEIN OF SARS-COV-2 VIRUS, AND METHOD FOR THEIR USE FOR THERAPY AND EMERGENCY PREVENTION OF DISEASES CAUSED BY SARS- COV-2 VIRUS | 2021 |
|
RU2763001C1 |
| SINGLE-DOMAIN NANO-ANTIBODIES AGAINST SPIKE PROTEIN OF SARS-CoV-2 VIRUS | 2021 |
|
RU2794141C2 |
| MEANS AND METHOD FOR THERAPY AND EMERGENCY PREVENTION OF DISEASES CAUSED BY THE SARS-COV-2 VIRUS BASED ON A RECOMBINANT ANTIBODY AND A HUMANIZED MONOCLONAL ANTIBODY | 2021 |
|
RU2769223C1 |
| HUMANIZED MONOCLONAL ANTIBODY SPECIFICALLY BINDING TO RBD S OF THE PROTEIN OF THE SARS-COV-2 VIRUS, AGENT AND METHOD FOR THERAPY AND EMERGENCY PREVENTION OF DISEASES CAUSED BY SARS-COV-2 VIRUS | 2021 |
|
RU2765731C1 |
| SINGLE-DOMAIN LLAMA ANTIBODY H5 AND ITS DERIVATIVE H5-Fc SPECIFICALLY BINDING THE RBD DOMAIN OF THE S-PROTEIN OF THE SARS-CoV-2 VIRUS POSSESSING VIRUS-NEUTRALIZING ACTIVITY | 2022 |
|
RU2793967C1 |
| EXPRESSION VECTOR BASED ON ADENO-ASSOCIATED VIRUS CARRYING RECOMBINANT ANTIBODY GENES AND ITS USE FOR PREVENTION OF DISEASES CAUSED BY INFLUENZA A VIRUS AND SARS-CoV-2 VIRUS | 2023 |
|
RU2817792C1 |
| EXPRESSION VECTOR BASED ON ADENO-ASSOCIATED VIRUS AND METHOD OF ITS USE FOR EMERGENCY PREVENTION AND PROPHYLAXIS OF DISEASES CAUSED BY SARS-CoV-2 VIRUS (VERSIONS) | 2022 |
|
RU2777404C1 |
| PLASMID GENETIC CONSTRUCT pET21a_SKP, WHICH PROVIDES EXPRESSION IN ESCHERICHIA COLI PROKARYOTIC SYSTEM OF RECOMBINANT SKP PROTEIN, AND RECOMBINANT PROTEIN SKP HAVING BROADLY NEUTRALIZING PROPERTIES OF SINGLE-DOMAIN NANOANTIBODY AGAINST SARS-CoV-2 | 2024 |
|
RU2839376C1 |
| MONOCLONAL ANTIBODY IC2 AND ITS ANTIGEN-BINDING FRAGMENT, SELECTIVELY BINDING RECEPTOR-BINDING DOMAIN OF SPIKE PROTEIN OF SARS-CoV-2 VIRUS, HAVING VIRUS-NEUTRALIZING ACTIVITY | 2023 |
|
RU2817697C1 |
| MONOCLONAL ANTIBODY IC1 AND ITS ANTIGEN-BINDING FRAGMENT, SELECTIVELY BINDING RECEPTOR-BINDING DOMAIN OF SPIKE PROTEIN OF SARS-CoV-2 VIRUS, HAVING VIRUS-NEUTRALIZING ACTIVITY | 2023 |
|
RU2817696C1 |
